Aurovela Fe 1/20 Shortage: What Providers and Prescribers Need to Know in 2026

Provider Briefing: Aurovela Fe 1/20 Availability in 2026

If your patients are reporting difficulty filling prescriptions for Aurovela Fe 1/20 (Norethindrone Acetate 1 mg / Ethinyl Estradiol 20 mcg / Ferrous Fumarate 75 mg, 28-day pack), you're hearing a real and ongoing problem. While Aurovela Fe 1/20 is not listed on the FDA Drug Shortage database, the practical availability of this specific generic at many retail pharmacies has been inconsistent since 2022.

This briefing covers the timeline, prescribing implications, current availability landscape, and tools to help your patients maintain uninterrupted access to contraception.

Timeline of Availability Issues

2022: Initial Reports

In mid-2022, patients began reporting that Walgreens pharmacies were telling them Aurovela Fe 1/20 was "discontinued." In reality, the drug remained FDA-approved and in active production by Aurobindo Pharma. Walgreens had shifted its preferred generic for the Norethindrone Acetate/Ethinyl Estradiol 1/20 formulation, leading to stock removal at many locations.

2023-2024: Broader Supply Chain Disruption

Supply chain disruptions affecting multiple generic oral contraceptive manufacturers led to intermittent shortages across several brands in this formulation class. CVS removed Aurovela from its preferred drug lists in certain regions in 2024, compounding availability challenges for patients specifically prescribed the Aurovela brand.

2025-2026: Stabilization With Gaps

Manufacturing output from Aurobindo has stabilized, but distribution remains uneven. The primary issue in 2026 is not manufacturing capacity but rather pharmacy purchasing decisions — many chain pharmacies have locked into contracts with competing generic manufacturers (Teva for Junel, Lupin for Blisovi, Novitium for Larin), effectively removing Aurovela from their shelves.

Prescribing Implications

Brand-Specific vs. Generic-Name Prescribing

One of the most impactful steps prescribers can take is to write prescriptions using the generic chemical name rather than a specific brand:

• Preferred: "Norethindrone Acetate/Ethinyl Estradiol 1 mg/20 mcg tablets with Ferrous Fumarate, 28-day pack"
• Less flexible: "Aurovela Fe 1/20" or any specific brand name

When a prescription specifies a brand name, some state pharmacy regulations and insurance systems may require that exact product. A generic-name prescription allows the dispensing pharmacist to fill with whichever AB-rated equivalent is in stock — Aurovela, Junel Fe 1/20, Microgestin Fe 1/20, Blisovi Fe 1/20, or Larin Fe 1/20.

Therapeutic Equivalence Considerations

All FDA-approved generics of Norethindrone Acetate/Ethinyl Estradiol 1 mg/20 mcg with Ferrous Fumarate are rated AB by the FDA, meaning they meet bioequivalence standards. Clinically, switching between these generics should not affect contraceptive efficacy. However, some patients may report subjective differences in side effects during the first 1-2 cycles after a switch, likely related to differences in inactive ingredients.

Avoiding "Dispense as Written" Unless Medically Necessary

Unless a patient has a documented adverse reaction to a specific generic formulation's inactive ingredients (e.g., a dye allergy), avoid marking prescriptions as "Dispense as Written" (DAW) for this medication. DAW designations significantly limit the pharmacist's ability to fill the prescription when the specified brand is unavailable.

Current Availability Picture

Based on pharmacy inventory data and patient reports in early 2026:

• Aurovela Fe 1/20 (Aurobindo): Inconsistently stocked at chain pharmacies; more reliably available at independent pharmacies and through mail-order services
• Junel Fe 1/20 (Teva): Widely available at most chain pharmacies
• Microgestin Fe 1/20 (Mayne): Broadly available
• Blisovi Fe 1/20 (Lupin): Available at most locations, with occasional regional shortages
• Larin Fe 1/20 (Novitium): Widely available and often the lowest-cost option with coupons

Independent pharmacies and mail-order pharmacies generally have more flexibility in sourcing specific brands through multiple distributors.

Cost and Access Considerations

Under the ACA contraceptive mandate, most insurance plans must cover FDA-approved oral contraceptives without cost-sharing. This applies to all generic versions of Norethindrone Acetate/Ethinyl Estradiol 1/20. Key cost data for uninsured or underinsured patients:

• Cash price: $27-$45 per 28-day pack (varies by brand and pharmacy)
• With discount coupons (GoodRx, SingleCare): $8-$15 per pack
• Patient assistance programs: NeedyMeds, RxAssist, and Planned Parenthood clinics can provide low-cost or free contraceptives for qualifying patients

For detailed pricing information to share with patients, refer them to our guide on saving money on Aurovela Fe 1/20.

Tools and Resources for Your Practice

Medfinder Provider Tools

Medfinder for Providers offers real-time pharmacy inventory search that can help your clinical staff locate in-stock pharmacies for patients at the point of prescribing. By checking availability before the patient leaves your office, you can proactively direct them to a pharmacy that has their medication.

Patient-Facing Resources

Consider sharing these resources with patients who are having difficulty filling their prescriptions:

• How to find Aurovela Fe 1/20 in stock near you
• Alternatives to Aurovela Fe 1/20
• Aurovela Fe 1/20 shortage update for patients

Telehealth Prescribing Partnerships

For patients in areas with persistent availability gaps, telehealth contraception services (e.g., Pandia Health, Nurx, SimpleHealth) maintain pharmacy partnerships designed for consistent supply chain access. These can be particularly useful for patients in rural or underserved areas.

Looking Ahead

The availability landscape for generic oral contraceptives continues to evolve. Key trends to watch in 2026:

• Generic consolidation: Ongoing mergers among generic manufacturers may further concentrate production of low-dose oral contraceptives
• Policy changes: State-level pharmacy regulations around generic substitution and contraceptive access continue to expand
• Digital tools: Real-time pharmacy inventory platforms like Medfinder are becoming standard workflow tools for clinical practices

Final Thoughts

The Aurovela Fe 1/20 availability issue is a distribution and formulary problem, not a manufacturing crisis. The most effective intervention prescribers can make is writing generic-name prescriptions that give pharmacists maximum flexibility. Combined with proactive availability checking through tools like Medfinder for Providers, you can help ensure your patients maintain uninterrupted access to their contraception.

For a practical workflow guide, see our companion article: How to help your patients find Aurovela Fe 1/20 in stock.